Skip to main content

Table 3 A comparison of the between combination and single effects of PMX and CFX on %cells with CAs, SCE/Cells, %MNBN, MI, PI, and NDI in human peripheral blood lymphocytes for 24- and 48-h treatment periods

From: In vitro genotoxicity and cytotoxicity of a particular combination of pemetrexed and cefixime in human peripheral blood lymphocytes

 

Treatment

 

Test substance

Time (h)

Concentration (μg/mL)

% Cells with CAs ± S.E.

SCE/Cell ± S.E.

%MNBN ± S.E.

MI ± S.E.

PI ± S.E.

NDI ± S.E.

PMXa

24

25

5.25 ± 0.25

9.52 ± 3.09

0.60 ± 0.07

3.29 ± 0.47

1.79 ± 0.15

1.27 ± 0.05

  

50

5.00 ± 1.08

4.73 ± 1.29

0.42 ± 0.14

3.53 ± 0.62

1.75 ± 0.14

1.28 ± 0.06

  

75

6.25 ± 0.62

3.67 ± 0.48

0.50 ± 0.12

3.25 ± 0.46

1.96 ± 0.09

1.19 ± 0.02

  

100

5.00 ± 1.08

3.42 ± 0.40

0.15 ± 0.06

3.73 ± 0.89

1.72 ± 0.14

1.21 ± 0.04

CFX

24

900

1.25 ± 0.75

5.49 ± 0.39

0.30 ± 0.04

3.20 ± 0.42

2.09 ± 0.09

1.51 ± 0.07

  

1600

0.75 ± 0.47

5.37 ± 0.52

0.22 ± 0.06

2.09 ± 0.32

1.84 ± 0.06

1.52 ± 0.04

  

2300

0.75 ± 0.25

5.85 ± 0.13

0.25 ± 0.06

2. 31 ± 0.44

1.95 ± 0.08

1.52 ± 0.09

  

3000

0.75 ± 0.47

6.09 ± 0.28

0.20 ± 0.07

2.19 ± 0.05

1.86 ± 0.05

1.46 ± 0.04

PMX + CFX

24

12.5 + 450

2.00 ± 0.40 d2

5.65 ± 0.77 d1

0.22 ± 0.02 d2

1.58 ± 0.25 d1e3

1.91 ± 0.04

1.24 ± 0.03 e2

  

25 + 800

3.25 ± 0.85 e1

4.28 ± 0.12

0.10 ± 0.04 d2

1.70 ± 0.07 d1

1.85 ± 0.09

1.17 ± 0.05 e3

  

37.5 + 1150

2.50 ± 1.04 d2

3.77 ± 0.73 e3

0.02 ± 0.02 d3e2

1.67 ± 0.34 d1

2.01 ± 0.09

1.17 ± 0.01 e3

  

50 + 1500

2.00 ± 0.70 d1

3.71 ± 0.69 e3

0.10 ± 0.04

1.25 ± 0.20 d3e1

1.99 ± 0.14

1.17 ± 0.01 e2

PMXa

48

25

2.25 ± 1.03

7.14 ± 2.11

0.55 ± 0.11

2.20 ± 0.49

1.88 ± 0.72

1.06 ± 0.21

  

50

3.00 ± 0.70

2.87 ± 0.20

0.25 ± 0.06

2.81 ± 0.62

1.65 ± 0.16

1.10 ± 0.26

  

75

2.50 ± 0.64

3.32 ± 0.29

0.05 ± 0.03

2.00 ± 0.51

1.70 ± 0.19

1.11 ± 0.02

  

100

1.00 ± 0.40

3.05 ± 0.33

0.10 ± 0.04

1.61 ± 0.68

1.53 ± 0.16

1.09 ± 0.24

CFX

48

900

1.25 ± 0.62

7.14 ± 0.90

0.15 ± 0.02

2.18 ± 0.18

1.93 ± 0.14

1.42 ± 0.04

  

1600

2.00 ± 0.91

6.23 ± 0.67

0.20 ± 0.04

2.28 ± 0.51

1.96 ± 0.08

1.37 ± 0.06

  

2300

1.50 ± 0.64

7.17 ± 1.00

0.20 ± 0.09

2.00 ± 0.52

1.81 ± 0.10

1.35 ± 0.07

  

3000

1.75 ± 0.47

7.19 ± 0.99

0.17 ± 0.11

1.70 ± 0.23

1.73 ± 0.08

1.29 ± 0.05

PMX + CFX

48

12.5 + 450

1.25 ± 0.75

7.27 ± 1.52

0.12 ± 0.02 d3

0.70 ± 0.18 d1e2

1.48 ± 0.07 d1e3

1.09 ± 0.03 e3

  

25 + 800

1.25 ± 0.25 d3

3.82 ± 0.33

0.10 ± 0.04

0.84 ± 0.17 d2e2

1.38 ± 0.05 e3

1.09 ± 0.02 e3

  

37.5 + 1150

0.75 ± 0.47 d2

3.28 ± 0.26 e2

0.12 ± 0.04

0.54 ± 0.19 d1e2

1.22 ± 0.05 d2e3

1.04 ± 0.01 d1e3

  

50 + 1500

0.50 ± 0.50

4.00 ± 0.17 e1

0.05 ± 0.02

0.22 ± 0.14 d2e2

1.26 ± 0.05 d3e3

1.05 ± 0.01 e3

  1. All data are expressed as mean ± S.E; n = 4.
  2. aIstifli and Topaktas 2013.
  3. d, significant from pemetrexed (PMX) separately; e, significant from cefixime (CFX) separately.
  4. d1e1: p < 0.05; d2e2: p < 0.01; d3e3: p < 0.001.